PIK3C2G IDG kinase ARCHS4 coexpression (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with PIK3C2G IDG kinase ARCHS4 coexpression.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with PIK3C2G IDG kinase ARCHS4 coexpression.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with PIK3C2G IDG kinase ARCHS4 coexpression.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with PIK3C2G IDG kinase ARCHS4 coexpression.

Results found

Linked to

 

Label

Description

 

Gene

Rho associated coiled-coil containing protein kinase 1 pseudogene 1

Gene

AZGP1 pseudogene 1

Gene

aspartic peptidase retroviral like 1

Gene

deleted in esophageal cancer 1

Gene

complement 3 precursor pseudogene

Gene

tigger transposable element derived 1

Gene

serpin family A member 10

Gene

coiled-coil domain containing 144A

Gene

UDP glucuronosyltransferase family 1 member A3

Gene

urotensin 2B

  • Gene

    Rho associated coiled-coil containing protein kinase 1 pseudogene 1


  • Gene

    AZGP1 pseudogene 1


  • Gene

    aspartic peptidase retroviral like 1


  • Gene

    deleted in esophageal cancer 1


  • Gene

    complement 3 precursor pseudogene


  • Gene

    tigger transposable element derived 1


  • Gene

    serpin family A member 10


  • Gene

    coiled-coil domain containing 144A


  • Gene

    UDP glucuronosyltransferase family 1 member A3


  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.